Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 175

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Prediction of drug combination effects with a minimal set of experiments

Open access
Ianevski, Aleksandr, Giri, Anil K., Gautam, Prson, Kononov, Alexander, Potdar, Swapnil, Saarela, Jani, Wennerberg, Krister, Aittokallio, Tero · 2019 · Nature Machine Intelligence

Abstract

High-throughput drug combination screening provides a systematic strategy to discover unexpected combinatorial synergies in pre-clinical cell models. However, phenotypic combinatorial screening with multi-dose matrix assays is experimentally expensive, especially when the aim is to identify selective combination synergies across a large panel of cell lines or patient samples. Here, we implement DECREASE, an efficient machine learning model that requires only a limited set of pairwise dose–response measurements for accurate prediction of drug combination synergy in a given sample. Using a compendium of 23,595 drug combination matrices tested in various cancer cell lines and malaria and Ebola infection models, we demonstrate how cost-effective experimental designs with DECREASE capture almost the same degree of information for synergy and antagonism detection as the fully measured dose–response matrices. Measuring only the matrix diagonal provides an accurate and practical option for combinatorial screening. The minimal-input web implementation enables applications of DECREASE to both pre-clinical and translational studies. Drug combinations are often an effective means of managing complex diseases, but understanding the synergies of drug combinations requires extensive resources. The authors developed an efficient machine learning model that requires only a limited set of pairwise dose–response measurements for the accurate prediction of synergistic and antagonistic drug combinations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42256-019-0122-4

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 39

  1. Webster, R. M. Combination therapies in oncology. Nat. Rev. Drug Discov. 15, 81–82 (2016). · DOI
  2. Lehár, J. et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659–666 (2009). · DOI · Paper page
  3. Radic-Sarikas, B. et al. Combinatorial drug screening identifies Ewing sarcoma-specific sensitivities. Mol. Cancer Ther. 16, 88–101 (2017). · DOI
  4. Pelaia, G., Vatrella, A. & Maselli, R. The potential of biologics for the treatment of asthma. Nat. Rev. Drug Discov. 11, 958–972 (2012). · DOI · Paper page
  5. Chakradhar, S. All in one: researchers create combination drugs for diabetes and obesity. Nat. Med. 22, 694–696 (2016). · DOI
  6. Chandrasekaran, S. et al. Chemogenomics and orthology-based design of antibiotic combination therapies. Mol. Syst. Biol. 12, 872 (2016). · DOI
  7. Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl Acad. Sci. USA 100, 7977–7982 (2003). · DOI · Paper page
  8. Mott, B. T. et al. High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Sci. Rep. 5, 13891 (2015).
  9. Mathews Griner, L. A. et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl Acad. Sci. USA 111, 2349–2354 (2014). · DOI · Paper page
  10. Janzen, W. P. Screening technologies for small molecule discovery: the state of the art. Chem. Biol. 21, 1162–1170 (2014). · DOI
  11. He, L. et al. Patient-customized drug combination prediction and testing for T-cell prolymphocytic leukemia patients. Cancer Res. 78, 2407–2418 (2018). · DOI
  12. Roy, A. et al. Open access high throughput drug discovery in the public domain: a Mount Everest in the making. Curr. Pharm. Biotechnol. 11, 764–778 (2010). · DOI
  13. Kurtz, S. E. et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc. Natl Acad. Sci. USA 114, 7554–7563 (2017). · DOI
  14. Yu, D. et al. Identification of synergistic, clinically achievable, combination therapies for osteosarcoma. Sci. Rep. 5, 16991 (2015).
  15. Horn, T. et al. High-order drug combinations are required to effectively kill colorectal cancer cells. Cancer Res. 76, 6950–6963 (2016). · DOI
  16. Chou, A. et al. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut 67, 2142–2155 (2018). · DOI
  17. Sun, W. et al. Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria. Emerg. Microbes Infect. 5, e116 (2016).
  18. Shehata, M. et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 116, 2513–2521 (2010). · DOI
  19. Tan, X. et al. Systematic identification of synergistic drug pairs targeting HIV. Nat. Biotechnol. 30, 1125–1130 (2012). · DOI
  20. Di Veroli, G. Y. et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32, 2866–2868 (2016). · DOI · Paper page
  21. Ianevski, A., He, L., Aittokallio, T. & Tang, J. SynergyFinder: a web application for analyzing drug combination dose–response matrix data. Bioinformatics 33, 2413–2415 (2017). · DOI · Paper page
  22. Loewe, S. The problem of synergism and antagonism of combined drugs. Arzneimiettelforschung 3, 286–290 (1953).
  23. Bliss, C. I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585–615 (1939). · DOI · Paper page
  24. Berenbaum, M. C. What is synergy? Pharmacol. Rev. 41, 93–141 (1989).
  25. Chevereau, G. & Bollenbach, T. Systematic discovery of drug interaction mechanisms. Mol. Syst. Biol. 11, 807 (2015). · DOI
  26. Zimmer, A. et al. Prediction of multidimensional drug dose responses based on measurements of drug pairs. Proc. Natl Acad. Sci. USA 113, 10442–10447 (2016). · DOI
  27. Eziefula, A. C. Artesunate-mefloquine: a malaria treatment for African children? Lancet Infect. Dis. 16, 1086–1087 (2016). · doi:10.1016/s1473-3099(16)30125-6
  28. Dyall, J. et al. Identification of combinations of approved drugs with synergistic activity against Ebola virus in cell cultures. J. Infect. Dis. 218, S672–S678 (2018). · DOI
  29. Weinstein, Z. B. et al. Prediction of synergistic drug combinations. Curr. Opin. Syst. Biol. 4, 24–28 (2015). · DOI
  30. Szwajda, A. et al. Systematic mapping of kinase addiction combinations in breast cancer cells by integrating drug sensitivity and selectivity profiles. Chem. Biol. 22, 1144–1155 (2015). · DOI
  31. Mullard, A. Microfluidics platform lowers barrier to drug combination screening. Nat. Rev. Drug Discov. 17, 691–692 (2018). · doi:10.1038/nrd.2018.161
  32. Gautam, P. et al. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. Mol. Cancer 15, 34 (2016).
  33. Gadagkar, S. R. & Call, G. B. Computational tools for fitting the Hill equation to dose–response curves. J. Pharmacol. Toxicol. Methods 71, 68–76 (2015). · DOI
  34. Hill, A. V. The possible effects of the aggregation of the molecules of hemoglobin on its dissociation curves. J. Physiol. 40, 4–7 (1910).
  35. Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose–response analysis using R. PLoS One 10, e0146021 (2015). · DOI · Paper page
  36. Wang, Y. X. et al. Non-negative matrix factorization: a comprehensive review. IEEE Trans. Knowl. Data Eng. 25, 1336–1353 (2013). · DOI · Paper page
  37. Venter, J. H. On estimation of the mode. Ann. Math. Stat. 38, 1446–1455 (1967). · DOI
  38. Tang, J., Wennerberg, K. & Aittokallio, T. What is synergy? The Saariselkä agreement revisited. Front. Pharmacol. 6, 181 (2015). · DOI · Paper page
  39. Bischl, B. et al. mlrMBO: a modular framework for model-based optimization of expensive black-box functions. Preprint at https://arxiv.org/abs/1703.03373 (2017). · DOI

Cited by

See all 175

Metadata

Authors
Ianevski, A., Giri, A. K., Gautam, P., Kononov, A., Potdar, S., Saarela, J., Wennerberg, K., & Aittokallio, T.
Venue
Nature Machine Intelligence
Published
2019-12-09
Volume
1
Issue
12
Pages
568-577
ISSN
2522-5839 (ISSN-L)
OpenAlex
W2992010506
Cited by
175
References
8
FWCI
9.82
Type
journal article
Language
en
Open access
green
Licence
Funders
Academy of Finland (292611, 279163, 295504, 310507, 313267, 326238)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prediction of drug combination effects with a minimal set of experiments. https://app.cochat.ai/papers/10.1038/s42256-019-0122-4
The paper
Ianevski, A., Giri, A. K., Gautam, P., Kononov, A., Potdar, S., Saarela, J., Wennerberg, K., & Aittokallio, T. (2019). Prediction of drug combination effects with a minimal set of experiments. Nature Machine Intelligence. https://doi.org/10.1038/s42256-019-0122-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.